Janssen Pharmaceutical Companies of Johnson & Johnson and the non-profit Global Alliance for TB Drug Development (TB Alliance) share their expertise and resources in the development of TMC207, which could become the first TB drug with a new mechanism of action in 40 years. Under the terms of the agreement, Janssen is developing TMC207 for the treatment of MDR-TB and, on approval, will work with global (Stop TB Partnership, WHO, etc.), regional and local stakeholders to ensure the product is appropriately used in accordance with international standards, affordable and available to patients in need. The agreement grants the TB Alliance a royalty-free license for the worldwide development and access to TMC207 in the field of drug-susceptible TB. Janssen and the TB Alliance will share expertise and resources in the development of TMC207. A number of Early Bactericidal Activity (EBA) studies have been conducted to establish dose finding and to facilitate new regimen selection. Drug-Drug Interaction (DDI) studies are also underway. In addition, Janssen collaborates with the TB Alliance in a discovery research program to identify other new compounds for the treatment of TB. The rights for the newly discovered compounds for the treatment of tuberculosis will belong to the TB Alliance under a royalty-free license.